The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, single-arm evaluation of palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who have experienced CINV during the previous cycle of low emetogenic chemotherapy (LEC).
A. W. Komorowski
No relevant relationships to disclose
G. R. Morrow
No relevant relationships to disclose
R. Ahmed
Employment or Leadership Position - Eisai
D. Cox
Employment or Leadership Position - Eisai
P. J. Hesketh
Consultant or Advisory Role - Eisai; Merck
Research Funding - Eisai; Merck